Pridefine

Pridefine (AHR-1,118) is a drug which was investigated as an antidepressant in the late 1970s and early 1980s, but was never marketed.[1] It acts as a balanced reuptake inhibitor of serotonin, dopamine, and norepinephrine, and also has some weak releasing activity.[1][2][3]

Pridefine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • 3-(Diphenylmethylidene)-1-ethylpyrrolidine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H21N
Molar mass263.384 g·mol−1

In clinical trials pridefine was found to be as efficacious as the tricyclic antidepressants amitriptyline and imipramine in the treatment of major depressive disorder but was much more tolerable in comparison and also had an earlier onset of action.[1] It has been shown to be effective in the treatment of alcoholism as well.[1]

See also

References
  1. Vosmer G, DeMet EM, Halaris AE (1980). "Action of the antidepressant pridefine (AHR-1118) on biogenic amines in the rat brain". Biochemical Pharmacology. 29 (19): 2557–62. doi:10.1016/0006-2952(80)90066-0. PMID 7426062.
  2. Halaris AE, Demet EM (1980). "Open trial evaluation of a pyrrolidine derivative (AHR-1118) on norepinephrine metabolism". Progress in Neuro-Psychopharmacology. 4 (1): 43–9. doi:10.1016/0364-7722(80)90060-0. PMID 7406986.
  3. DeMet EM, Vosmer G, Halaris AE (1981). "Noncompetitive amine uptake inhibition by the new antidepressant pridefine". Journal of Neurochemistry. 36 (3): 917–23. doi:10.1111/j.1471-4159.1981.tb01682.x. PMID 7205281. S2CID 1802928.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.